Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Asthma I: Introduction

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

Antibody Structure

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...

Asthma-I: Introduction

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Autonomous IL-36R signaling in neutrophils activates potent antitumor effector functions.

The Journal of clinical investigation·2023

Same author

Correction: Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.

Leukemia·2020

Same author

An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma.

Cell·2020

Same author

Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials.

Immunity·2020

Same author

An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma.

Cell·2019

Same author

Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.

Leukemia·2018

Search research articles

Related Experiment Video

Updated: May 30, 2026

Detection of True IgE-expressing Mouse B Lineage Cells

Detection of True IgE-expressing Mouse B Lineage Cells

Published on: December 1, 2014

Immunoglobulin E receptor signaling and asthma.

¹Department of Immunology, Genentech, Incorporated, South San Francisco, California 94080, USA. lawren@gene.com

The Journal of Biological Chemistry

|July 30, 2011

Summary

Elevated immunoglobulin E (IgE) and its receptor FcεRI are key in allergic asthma. Blocking IgE improves asthma control by reducing FcεRI activation.

Area of Science:

Immunology
Allergy Research
Asthma Pathophysiology

Background:

Allergic asthma is characterized by elevated immunoglobulin E (IgE) levels and sensitization to allergens.
IgE binds to the high-affinity Fc receptor I (FcεRI) on immune cells like mast cells and basophils.
Activation of FcεRI by antigen cross-linking initiates inflammatory responses central to asthma.

Purpose of the Study:

To investigate the role of IgE and FcεRI signaling in allergic asthma.
To explore the therapeutic potential of targeting IgE-FcεRI interactions for asthma control.

Main Methods:

Review of IgE-FcεRI binding and downstream signaling pathways.
Analysis of therapeutic neutralization of serum IgE in moderate-to-severe allergic asthma.

More Related Videos

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Related Experiment Videos

Last Updated: May 30, 2026

Detection of True IgE-expressing Mouse B Lineage Cells

Detection of True IgE-expressing Mouse B Lineage Cells

Published on: December 1, 2014

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Main Results:

Therapeutic IgE neutralization in asthmatics reduced asthma exacerbations.
This reduction was linked to decreased FcεRI expression and activation on immune cells.
Improved asthma control was observed following IgE-targeted therapy.

Conclusions:

Understanding IgE receptor signaling is crucial for asthma treatment.
Targeting IgE and FcεRI offers a promising therapeutic strategy for allergic asthma.
Further research into IgE receptor signaling may yield novel asthma therapeutics.